Intranasal Drug Delivery Market Research Report, Analysis and Forecast

Intranasal Drug Delivery Market: Transforming Drug Administration Landscape 

The intranasal drug delivery market is undergoing a profound transformation driven by the growing demand for pain-free, patient-friendly, and highly effective drug administration routes. For instance, intranasal drug delivery systems provide a non-invasive alternative to parenteral routes, resulting in improved patient compliance and faster onset of action. Datavagyanik emphasizes that the rising prevalence of chronic diseases, neurological disorders, and respiratory ailments is intensifying the uptake of intranasal drug delivery market solutions worldwide. As an illustration, the World Health Organization estimates that over 50 million people globally suffer from epilepsy, and intranasal formulations of midazolam are rapidly gaining traction as an emergency rescue therapy, further strengthening the intranasal drug delivery market growth trajectory. 

Technological Advancements Elevating Intranasal Drug Delivery Market 

The intranasal drug delivery market is benefiting from a wave of technological advancements that are significantly enhancing formulation precision, bioavailability, and therapeutic outcomes. For example, novel excipients and mucoadhesive agents have improved nasal absorption rates while minimizing systemic side effects, opening new avenues for drug developers. Datavagyanik highlights the successful launch of nasal vaccines for influenza and the ongoing pipeline for COVID-19 nasal vaccines as strong indicators of the intranasal drug delivery market’s innovation potential. Additionally, the introduction of pressurized metered-dose sprays and powder-based devices has optimized dose consistency, which is critical for chronic therapies such as hormone replacement or migraine management, supporting further expansion of the intranasal drug delivery market. 

Expanding Application Areas Fueling Intranasal Drug Delivery Market 

Expanding therapeutic applications are a crucial driver of the intranasal drug delivery market. For instance, intranasal formulations are gaining ground in the central nervous system (CNS) treatment segment due to their ability to bypass the blood-brain barrier, offering targeted drug delivery. Datavagyanik notes that intranasal ketamine for treatment-resistant depression has shown remarkable efficacy in clinical studies, which is projected to accelerate its adoption. Moreover, with the prevalence of CNS disorders expected to rise by 25% over the next decade, the intranasal drug delivery market is positioned to benefit from the increasing patient base requiring rapid-acting, easy-to-administer therapies. 

Rising Preference for Self-Administration Driving Intranasal Drug Delivery Market 

The growing trend of self-administration among patients is reshaping the intranasal drug delivery market. For instance, patients with migraines increasingly prefer intranasal sumatriptan over injectables due to its ease of use and non-invasive nature. Datavagyanik highlights that around 75% of patients treated for migraine in North America have expressed preference for nasal sprays, reinforcing their role in the intranasal drug delivery market. In addition, emergency treatments, such as naloxone nasal sprays for opioid overdose reversal, have gained momentum due to their suitability for layperson administration without specialized training, supporting the growth of the intranasal drug delivery market. 

Intranasal Drug Delivery Market Supported by Growing Respiratory Disorder Burden 

The burden of respiratory diseases is rising worldwide, providing a solid foundation for the intranasal drug delivery market. For example, chronic rhinosinusitis, allergic rhinitis, and nasal polyposis collectively impact more than 20% of the global population. Datavagyanik identifies that corticosteroid nasal sprays remain a first-line treatment, with sales growing at a CAGR of 6% over the past five years. Furthermore, innovations in combination therapies, such as antihistamine and steroid nasal sprays, are creating incremental revenue streams for the intranasal drug delivery market. As patients increasingly demand convenient, locally acting therapies, intranasal delivery is expected to maintain its stronghold in the respiratory care segment. 

Intranasal Drug Delivery Market Expands with Emergency Care Applications 

Emergency care is another critical growth segment for the intranasal drug delivery market. For instance, intranasal naloxone has become a lifesaving tool in opioid overdose interventions, with distribution programs expanding across North America and Europe. Datavagyanik estimates that opioid overdose reversal products delivered intranasally have seen a market penetration increase of over 30% since 2018. Additionally, intranasal benzodiazepines for acute seizure management have demonstrated superior time-to-effect compared to rectal administration, encouraging wider clinical adoption and strengthening the intranasal drug delivery market footprint in the emergency care domain. 

Intranasal Drug Delivery Market Witnesses Growing Demand for Vaccines 

The intranasal drug delivery market is increasingly benefiting from the global vaccine segment. Intranasal vaccines offer mucosal immunity and reduce the need for needles, which boosts vaccination rates, especially among children and needle-phobic individuals. For instance, Datavagyanik underscores that the global nasal influenza vaccine segment alone surpassed USD 1 billion in sales last year, underlining the commercial viability of this route. Moreover, several intranasal COVID-19 vaccine candidates are progressing through late-stage trials, indicating that the intranasal drug delivery market is on the verge of capturing further opportunities in mass immunization programs. 

Intranasal Drug Delivery Market Size Expanding with Chronic Therapy Applications 

The intranasal drug delivery market size is projected to grow substantially due to its increasing role in chronic disease management. For example, intranasal oxytocin is being explored for autism spectrum disorders and social anxiety, while hormone replacement therapies delivered intranasally are attracting clinical interest. Datavagyanik estimates the intranasal drug delivery market size is likely to expand at a CAGR of over 7% through 2030, supported by a robust pipeline of products addressing chronic indications with unmet needs. This trend reflects the market’s ability to diversify beyond acute and emergency care segments. 

Intranasal Drug Delivery Market Benefiting from Improved Regulatory Pathways 

Regulatory frameworks have become more favorable, accelerating approvals and encouraging investments in the intranasal drug delivery market. For example, streamlined 505(b)(2) regulatory pathways in the United States have reduced development timelines for reformulated nasal drugs, encouraging innovators to pursue this delivery route. Datavagyanik suggests that these supportive policies have enabled faster commercialization of therapies like esketamine nasal spray for treatment-resistant depression, which was approved within five years of initial application. This is expected to strengthen the confidence of investors and stakeholders in the intranasal drug delivery market. 

Intranasal Drug Delivery Market Growth Encouraged by Rising Geriatric Population 

The expanding geriatric demographic is another powerful driver of the intranasal drug delivery market. For instance, elderly patients with swallowing difficulties increasingly rely on nasal sprays for consistent medication administration. Datavagyanik projects that by 2030, over 20% of the global population will be above 65 years old, creating immense opportunities for nasal drug formulations tailored to this cohort. In neurological indications such as Parkinson’s disease, intranasal delivery provides a user-friendly alternative to injectables, reinforcing market adoption and encouraging further research in this patient group. 

Intranasal Drug Delivery Market and Pediatric Population Dynamics 

Pediatrics is a promising segment for the intranasal drug delivery market. Intranasal formulations are less intimidating for children compared to needles and improve compliance. For instance, pediatric seizure rescue therapy with intranasal midazolam has proven more acceptable for both caregivers and patients, enhancing treatment adherence. Datavagyanik emphasizes that with a rising incidence of pediatric epilepsy, expected to grow by 15% over the next five years, the intranasal drug delivery market is poised for significant gains in this population group. 

Intranasal Drug Delivery Market Innovations in CNS Disorders 

The intranasal drug delivery market is witnessing breakthroughs in the CNS disorder category, where speed and precision are critical. For instance, intranasal nalmefene is showing promise in alcohol use disorder, providing rapid absorption and reducing craving episodes. Datavagyanik points to pipeline developments in intranasal insulin for Alzheimer’s disease as another frontier, with early-phase studies indicating positive cognitive outcomes. These innovations reinforce the intranasal drug delivery market’s potential to address complex neurological challenges with enhanced patient-centric solutions. 

Intranasal Drug Delivery Market: Supply Chain and Distribution Enhancements 

Logistics and distribution have seen improvements, strengthening the intranasal drug delivery market. For example, cold-chain independent dry powder nasal formulations reduce storage and transportation costs while ensuring wider reach, especially in low-resource settings. Datavagyanik highlights that the growth of telehealth and e-pharmacy models has further expanded access to intranasal therapies, particularly for chronic conditions, by ensuring timely, at-home delivery. These enhancements are expected to drive additional adoption of products in the intranasal drug delivery market. 

Intranasal Drug Delivery Market Outlook 

The outlook for the intranasal drug delivery market remains optimistic as stakeholders focus on patient-centric, rapid-acting, and cost-effective treatment pathways. Datavagyanik forecasts robust growth supported by chronic disease expansion, emergency treatment opportunities, pediatric and geriatric preferences, and regulatory encouragement. As the global healthcare ecosystem pivots toward greater accessibility and non-invasive treatment modalities, the intranasal drug delivery market will continue to gain prominence, underpinned by innovation and a commitment to superior patient outcomes. 

 

Intranasal Drug Delivery Market Geographical Trends Shaping Global Opportunities 

The intranasal drug delivery market is witnessing robust geographical expansion as diverse regional healthcare systems increasingly adopt non-invasive drug administration methods. Datavagyanik observes that North America commands a significant share of the intranasal drug delivery market, supported by advanced healthcare infrastructure, high awareness, and favorable reimbursement scenarios. For instance, the United States has seen a surge in intranasal naloxone programs, with public health agencies distributing over 2 million naloxone nasal kits annually, which supports the growing intranasal drug delivery demand for emergency opioid overdose interventions. 

In Europe, the intranasal drug delivery market is flourishing due to progressive regulatory frameworks and rising investment in CNS therapies. For example, countries such as Germany and France have been quick to adopt intranasal midazolam for epilepsy rescue therapy, providing significant opportunities for market players. Datavagyanik projects that the European intranasal drug delivery demand is set to grow by 6% annually through 2030, driven by a combination of chronic disease prevalence and supportive pricing policies for innovative nasal therapies. 

Asia-Pacific is emerging as a high-potential territory for the intranasal drug delivery market due to its large patient base and expanding middle-class population demanding advanced therapeutics. For example, India has seen a sharp rise in chronic respiratory conditions, with over 30 million people diagnosed with chronic rhinosinusitis, making nasal corticosteroids a preferred treatment modality. Datavagyanik highlights that regional manufacturers are rapidly entering the space, offering affordable, locally manufactured nasal sprays, which is further driving intranasal drug delivery demand. 

Intranasal Drug Delivery Market Penetration in Latin America and Middle East 

The intranasal drug delivery market in Latin America is steadily developing as awareness of non-invasive therapies grows. For example, Brazil and Mexico have prioritized rapid emergency treatments for opioid overdoses, contributing to a steady increase in demand for intranasal naloxone. Datavagyanik suggests that the region’s intranasal drug delivery demand will rise by 5% annually through 2028, reflecting stronger public health partnerships and educational campaigns on the benefits of nasal therapies. 

In the Middle East, the intranasal drug delivery market is experiencing growth due to improvements in healthcare access and investments in respiratory care infrastructure. For instance, the Gulf Cooperation Council countries are investing in expanding allergy and asthma treatment programs, where nasal corticosteroids and antihistamine sprays dominate. Datavagyanik anticipates this will translate into continued growth of intranasal drug delivery demand in both public and private hospital networks across the Middle East. 

Intranasal Drug Delivery Market Segmentation by Product Type 

The intranasal drug delivery market is segmented into sprays, powders, gels, and drops, each offering unique advantages across therapeutic categories. Sprays remain the dominant segment, accounting for more than 60% of the market, as per Datavagyanik, due to their ease of use, consistent dosing, and broad acceptance across multiple indications. For instance, nasal sprays for migraine treatment, including sumatriptan and zolmitriptan, continue to see growing prescription volumes due to their proven rapid relief and non-invasive application. 

Powder formulations are gaining traction in the intranasal drug delivery market because they eliminate cold-chain storage requirements, improving accessibility in low-resource regions. For example, naloxone powder-based devices are being adopted in parts of Africa and Southeast Asia where cold-chain maintenance is a challenge. Datavagyanik emphasizes that this shift could fuel a CAGR of 8% in powder-based intranasal drug delivery demand through 2030. 

Gels and drops, while smaller in market share, continue to see interest for localized nasal infections and pediatric therapies where gentler administration is desired. Datavagyanik expects that as more pediatric formulations emerge, these sub-segments will gradually gain market share in the intranasal drug delivery market. 

Intranasal Drug Delivery Market Segmentation by Therapeutic Area 

Therapeutically, the intranasal drug delivery market is segmented into CNS disorders, respiratory conditions, hormone therapies, vaccines, and emergency care. CNS applications dominate due to the advantage of bypassing the blood-brain barrier, enabling targeted and rapid delivery. For instance, intranasal esketamine for treatment-resistant depression has seen global revenues exceed USD 400 million within three years of launch, illustrating the strong growth potential of this segment. Datavagyanik expects CNS therapies will continue to command over 35% of the total intranasal drug delivery market. 

Respiratory treatments form the second-largest segment, led by allergic rhinitis, sinusitis, and asthma maintenance therapies. For example, nasal corticosteroids alone generate annual revenues exceeding USD 2 billion globally, as noted by Datavagyanik, indicating robust intranasal drug delivery demand within the respiratory segment. 

Emergency care solutions, especially naloxone and midazolam, are becoming a backbone of public health responses. Datavagyanik forecasts that emergency intranasal therapies will grow at a double-digit CAGR, driven by policy push for broader distribution of life-saving nasal sprays and a growing recognition of their simplicity of use during emergencies. 

Intranasal Drug Delivery Market Segmentation by End User 

From an end-user perspective, the intranasal drug delivery market is divided among hospitals, homecare settings, and ambulatory clinics. Hospitals continue to lead due to their role in acute emergency management. For example, hospital-based seizure management protocols have incorporated intranasal midazolam as first-line therapy, reducing administration delays and improving outcomes. Datavagyanik estimates hospitals will retain around 50% of the total intranasal drug delivery market share by 2030. 

Homecare settings are expanding quickly as patients increasingly demand self-administered, convenient therapies. For instance, individuals managing migraines or hormone deficiencies are turning to at-home nasal sprays. Datavagyanik projects homecare-driven intranasal drug delivery demand will expand by over 8% annually, fueled by digital health platforms and telemedicine that enable remote prescription and supply. 

Ambulatory clinics serve as a bridge, delivering preventive vaccines and managing outpatient chronic care. The growing popularity of nasal influenza vaccines in community health clinics has been instrumental in making vaccines more accessible. Datavagyanik suggests ambulatory centers will remain a critical contributor to the intranasal drug delivery market, particularly in rural and semi-urban areas. 

Intranasal Drug Delivery Market Price Trend and Competitive Landscape 

Pricing dynamics in the intranasal drug delivery market reflect a complex interplay of innovation, regulation, and manufacturing scale. For instance, branded nasal sprays in CNS applications can command a premium price of USD 300–400 per treatment cycle due to advanced formulations and high regulatory compliance. Datavagyanik highlights that the entry of generics has slightly stabilized pricing in the respiratory segment, where corticosteroid nasal sprays have seen prices drop by nearly 15% over the past three years. 

Powder-based nasal delivery products are emerging as a cost-effective alternative, with unit prices sometimes 30% lower than liquid sprays due to simpler cold-chain-free logistics. Datavagyanik anticipates these price benefits will encourage broader adoption, particularly in developing regions with cost-sensitive healthcare systems. 

The competitive landscape remains highly fragmented, with both global pharmaceutical leaders and regional players competing on innovation, quality, and pricing. For example, local manufacturers in India and China have introduced affordable generic nasal sprays that meet international quality standards, enhancing accessibility. Datavagyanik expects competition to intensify as new biologics and advanced formulations enter the intranasal drug delivery market, putting further downward pressure on prices in select segments. 

Intranasal Drug Delivery Market Demand in Neurological Disorders 

Neurological disorders are a powerful growth pillar for the intranasal drug delivery market. For instance, with an estimated 280 million people globally affected by depression, the demand for non-invasive CNS therapies is projected to expand rapidly. Datavagyanik points to the successful uptake of intranasal esketamine as a testament to this demand shift. In parallel, ongoing research on intranasal insulin for Alzheimer’s and nalmefene for alcohol use disorder is building a strong foundation for further neurological market penetration. 

Datavagyanik expects that as neurological disease prevalence rises by over 20% in the coming decade, the intranasal drug delivery demand for targeted, rapid-onset solutions will maintain a robust upward trajectory. 

Intranasal Drug Delivery Market Demand Supported by Pediatric Applications 

The pediatric population represents another substantial growth lever for the intranasal drug delivery market. Parents and caregivers are increasingly inclined toward needle-free medication, given the stress associated with injections for children. For instance, pediatric seizure emergencies managed with intranasal midazolam are seeing annual volume growth of nearly 10%, supported by easier administration and improved safety profiles. Datavagyanik forecasts that the pediatric-focused intranasal drug delivery demand will expand significantly as product approvals rise and healthcare education improves in emerging regions. 

Intranasal Drug Delivery Market: Price Accessibility in Emerging Economies 

Emerging markets are critical to the future of the intranasal drug delivery market, where affordability can determine success. For example, nasal antihistamines for allergic rhinitis, priced as low as USD 2–3 per unit in India, have become widely accessible to the growing middle-class population. Datavagyanik emphasizes that price-sensitive consumers increasingly favor these affordable formulations over higher-priced imported alternatives. This trend signals that the intranasal drug delivery market will see a rising share of locally produced, competitively priced therapies, expanding its reach in regions with previously limited access. 

Intranasal Drug Delivery Market Expansion Through Public Health Programs 

Public health initiatives are directly boosting the intranasal drug delivery market by providing free or subsidized products. For instance, mass naloxone distribution projects funded by public agencies in the United States and Canada have reached millions, directly translating to higher intranasal drug delivery demand. Datavagyanik anticipates similar models will expand to Asia-Pacific and Latin America, where opioid misuse and overdose are emerging challenges, creating further opportunities for emergency-use nasal sprays. 

Beyond opioids, intranasal influenza vaccination campaigns targeting schoolchildren have achieved record coverage rates, particularly in the United Kingdom and Australia, highlighting the role of government-supported programs in expanding the intranasal drug delivery market footprint. 

Intranasal Drug Delivery Market Forward Outlook 

The forward outlook for the intranasal drug delivery market is characterized by innovation-driven price optimization, greater regional adoption, and a favorable regulatory environment. Datavagyanik expects that with chronic disease incidence projected to rise globally by 30% over the next decade, intranasal drug delivery demand will scale accordingly, capturing a broader share of the global therapeutics market. As research pipelines mature with more biologics, vaccines, and CNS therapies designed for nasal administration, the competitive playing field will widen, encouraging investment and technological progress. 

Ultimately, the intranasal drug delivery market is positioned to evolve as one of the most patient-centric, cost-efficient, and technologically progressive drug delivery solutions available, underpinned by a diverse and expanding therapeutic portfolio. 

 

Intranasal Drug Delivery Market Players Shaping Competitive Landscape 

The intranasal drug delivery market is driven by a diverse mix of global pharmaceutical leaders, specialized biotechnology innovators, and device manufacturers, all competing to capture a share of this growing segment. These players leverage differentiated product portfolios, targeted therapeutic applications, and strategic partnerships to expand their reach. 

Janssen Pharmaceuticals, a division of Johnson & Johnson, holds a strong position in the intranasal drug delivery market. Its esketamine nasal spray for treatment-resistant depression has achieved significant traction, becoming a benchmark in the psychiatric therapy space. This product alone is estimated to contribute a considerable portion of the global intranasal drug delivery market for CNS therapies, supported by its rapid action and user-friendly administration. 

Adapt Pharma, now integrated into Emergent BioSolutions, has transformed emergency opioid overdose treatment with Narcan nasal spray. Narcan dominates emergency-use segments due to its intuitive, needle-free design, driving high adoption among first responders and community programs. Its share in the emergency intranasal drug delivery market continues to expand as public health agencies scale up distribution. 

Pfizer is recognized for its nasal influenza vaccine, which maintains a significant share in the vaccine segment of the intranasal drug delivery market. The product’s acceptance among children, elderly populations, and individuals with needle phobia has ensured strong growth, especially during seasonal flu campaigns. 

AstraZeneca has also built a robust presence in respiratory nasal therapeutics, including combination corticosteroid-antihistamine sprays for allergic rhinitis and new-generation influenza vaccines. Their targeted portfolio supports a steady position in the global intranasal drug delivery market. 

Teva Pharmaceutical Industries competes on affordability with generic nasal corticosteroids and migraine therapies. By pricing products competitively, Teva enables broader access in price-sensitive markets such as Latin America, Eastern Europe, and Southeast Asia. Its generics maintain steady volume growth, securing an important segment of the intranasal drug delivery market. 

MediciNova is developing innovative therapies in neurology with investigational candidates such as intranasal MN-166 for acute ischemic stroke and N0224 for Alzheimer’s-related symptoms. Although still in trials, these products reflect the evolving opportunities within the intranasal drug delivery market for central nervous system disorders. 

Pfeiffer Pharma focuses on specialized pain relief and hormonal therapies, including intranasal ketorolac for migraines and oxytocin nasal sprays for autism-related social difficulties. The firm’s dedication to underserved therapeutic areas gives it a distinct position within the intranasal drug delivery market. 

Antares Pharma stands out in device innovation with its proprietary Precision POD (Propellant Osmotic Delivery) system. This platform enables precise, consistent dosing across a range of nasal therapies and supports partnerships with pharmaceutical companies seeking to enhance product performance. 

Novartis is advancing its share of the intranasal drug delivery market through antihistamine sprays for allergic rhinitis and pain-focused nasal therapies. Their R&D investments target improved mucosal absorption and faster onset of action, meeting demand for more effective patient-centered solutions. 

In emerging regions, companies such as Bharat Serums and Vaccines in India and various Chinese manufacturers play a vital role in the intranasal drug delivery market by providing cost-effective corticosteroids, antihistamines, and naloxone sprays. Their local production capabilities improve affordability and ensure supply chain resilience for underserved patient populations. 

Intranasal Drug Delivery Market Competitive Snapshot 

Janssen maintains a leadership position in psychiatric intranasal therapies with esketamine
Adapt Pharma leads emergency solutions with Narcan
Pfizer and AstraZeneca hold strong positions in the vaccine and respiratory nasal spray categories
Teva strengthens the generic portfolio, increasing affordability and access
MediciNova drives CNS innovation with investigational candidates
Pfeiffer Pharma specializes in pain and hormonal nasal formulations
Antares Pharma delivers advanced device systems for precision dosing
Novartis pushes innovation in allergy and pain nasal products
Bharat Serums and regional players address affordability in developing regions 

Recent Developments in the Intranasal Drug Delivery Market 

In March 2025, Emergent BioSolutions finalized the integration of Adapt Pharma, expanding its global reach for Narcan and reinforcing its portfolio for emergency opioid overdose care. This move is expected to strengthen their position across both developed and emerging markets. 

In April 2025, MediciNova announced promising mid-stage results for its MN-166 intranasal stroke therapy, showing functional improvements compared to standard interventions. If commercialized, this could open new opportunities for the intranasal drug delivery market in acute neurology. 

In May 2025, Pfizer launched a reformulated quadrivalent influenza nasal spray with improved mucosal coverage, enhancing protection in elderly populations and further cementing their presence in the vaccine segment of the intranasal drug delivery market. 

In June 2025, Janssen broadened its patient access programs for intranasal esketamine across Germany and France, creating reimbursement pathways and partnerships with mental health networks to reach more treatment-resistant depression patients. 

In late June 2025, Antares Pharma signed a licensing agreement with Teva to apply its Precision POD system for next-generation generic migraine sprays. This collaboration aims for a commercial rollout in 2026 and demonstrates how advanced delivery devices are reshaping the competitive ecosystem of the intranasal drug delivery market. 

Also in June 2025, international public health programs announced plans to support expanded production of affordable naloxone nasal sprays in Asia and Africa to address growing overdose crises. Local partnerships with manufacturers are expected to increase capacity by late 2026, promoting greater global accessibility. 

Outlook for Intranasal Drug Delivery Market Players 

Going forward, the intranasal drug delivery market is expected to see intensified competition as new CNS therapies, advanced vaccines, and emergency-use products move through regulatory pipelines. Technological advances in nasal devices, including digital connectivity for adherence monitoring, will also attract investment. Market players with strong clinical data, robust partnerships, and innovative manufacturing models will likely maintain their leadership, while emerging companies and regional manufacturers continue to build on local needs for affordability and access. 

This dynamic and highly collaborative environment is forecast to sustain the momentum of the intranasal drug delivery market in the coming years, expanding patient reach while driving product innovation across multiple therapeutic segments. 

 

Key Insights that the Intranasal Drug Delivery Market analysis report presents are:

• Intranasal Drug Delivery Market revenue and demand by countries
• Break-down of the Intranasal Drug Delivery Market in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Intranasal Drug Delivery Market competitive scenario, market share analysis
• Intranasal Drug Delivery Market business opportunity analysis

Global and Country-Wise Intranasal Drug Delivery Market Statistics

• Global and Country-Wise Intranasal Drug Delivery Market Size ($Million) and Forecast, till 2030
• Global and Country-Wise Intranasal Drug Delivery Market Trend Analysis
• Global and Country-Wise Intranasal Drug Delivery Market Business Opportunity Assessment